OncoSec Medical

OncoSec is a clinical-stage biotechnology company founded in 2008, with its headquarters located in New Jersey, USA. The company is committed to developing cytokine-based intratumoral immunotherapies to stimulate the human immune system to target and attack cancer. OncoSec's immunotherapy agent TAVO can deliver DNA-based interleukin-12 (IL-12) intratumorally, a natural protein with potent immune-stimulating functions. TAVO uses electroporation technology, aiming to achieve controlled local expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body.